Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome.

ABSTRACT:

Background

Tandutinib (MLN 518, Millennium Pharmaceuticals, Cambridge, MA) is an orally active multitargeted tyrosine kinase inhibitor that is currently under evaluation for the treatment of glioblastoma and has been used in the treatment of leukemia. In prior clinical and animal studies, a dose-dependent muscular weakness has been observed with this drug, though the etiology of the weakness has not been defined.

Methods

Standard neurophysiologic techniques, including repetitive nerve stimulation, needle EMG, and single-fiber EMG, were used to evaluate patients who developed weakness while being treated with tandutinib and bevacizumab (Avastin, Genentech, South San Francisco, CA) for glioblastoma (NCT00667394).

Results

Six patients were observed to develop a reversibl

SUBMITTER: Lehky TJ 

PROVIDER: S-EPMC3034397 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature